vasospastic angina
Recently Published Documents


TOTAL DOCUMENTS

678
(FIVE YEARS 133)

H-INDEX

36
(FIVE YEARS 5)

2022 ◽  
Vol 11 (2) ◽  
pp. 299
Author(s):  
Sunwon Kim ◽  
Jong-Seok Lee ◽  
Yong-Hyun Kim ◽  
Jin-Seok Kim ◽  
Sang-Yup Lim ◽  
...  

Balloon-injured coronary segments are known to harbor abnormal vasomotion. We evaluated whether de novo coronary lesions treated using drug-coated balloon (DCB) are prone to vasospasm and how they respond to ergonovine and nitrate. Among 132 DCB angioplasty recipients followed, 89 patients underwent ergonovine provocation test at 6–9 months follow-up. Within-subject ergonovine- and nitrate-induced diameter changes were compared among three different sites: DCB-treated vs. angiographically normal vs. segment showing prominent vasoreactivity (spastic). No patient experienced clinically refractory vasospastic angina or symptom-driven revascularization during follow-up. Ergonovine induced vasospasm in seven patients; all were multifocal spasm either involving (n = 2) or rather sparing DCB-treated segments (n = 5). None showed focal spasm that exclusively involved DCB-treated lesions. Among 27 patients with vasospastic features, DCB-treated segments showed less vasoconstriction than spastic counterparts (p < 0.001). A total of 110 DCB-treated lesions were analyzed to assess vasomotor function. Vasomotor function, defined as a combined constrictor and dilator response, was comparable between DCB-treated and angiographically normal segments (p = 0.173), while significant differences were observed against spastic counterparts (p < 0.001). In our study, DCB-treated lesions were not particularly vulnerable to vasospasm and were found to have vasomotor function similar to angiographically normal segments, supporting safety of DCB-only strategy in treating de novo native coronary lesions.


Author(s):  
Taku Kumamoto ◽  
Hiroaki Kawano ◽  
Masaya Kurobe ◽  
Ryohei Akashi ◽  
Tsuyoshi Yonekura ◽  
...  

2021 ◽  
Vol 27 (12) ◽  
pp. S10
Author(s):  
Susana Barreiro Sacco ◽  
Valentina Celis ◽  
Ayoola Olayiwola ◽  
Diego Lugo

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Minsu Kim ◽  
Albert Youngwoo Jang ◽  
Pyung Chun Oh ◽  
Soon Yong Suh ◽  
Kyounghoon Lee ◽  
...  

AbstractThe diagnostic and prognostic role of nitroglycerin-induced dilation (NID) combined with ergonovine provocation test in patients with suspected VSA patients is not clear. A total of 438 consecutive patients who underwent the ergonovine provocation test for the diagnosis of vasospastic angina (VSA) were enrolled. Patients with VSA (n = 52) had a significantly greater coronary response to ergonovine (− 84.3 ± 10.5% vs. − 38.4 ± 17.9%, p < 0.001) and NID (26.3 ± 31.0% vs. 12.5 ± 19.0%, p < 0.001) than non-VSA patients. However, positive NID (more than 13.8% dilation, n = 170) showed a poor accuracy (AUC 0.64 [95% CI: 0.56–0.73], p = 0.001, sensitivity 60.4%, specificity 61.3%) for the diagnosis of VSA by ergonovine provocation test. Major adverse cardiovascular events (MACE) occurred more frequently in the VSA group than in the non-VSA group (9.6% vs. 2.2%, p = 0.006). In addition, the positive NID group showed a lower rate of MACE than the negative NID group (1.2% vs. 4.3%, p = 0.021). Interestingly, the group of VSA with negative NID had poor prognosis than any other combinations (Log-rank, p < 0.0001). Although NID had a limited role in the detection of VSA defined by ergonovine provocation test, NID combined with the ergonovine provocation test has an additive prognostic role in the clinical outcomes in patients with suspected VSA.


2021 ◽  
Vol 71 ◽  
pp. 102869
Author(s):  
David Song ◽  
Mohamed Abdelghffar ◽  
Tasur Seen ◽  
Andrew Kim ◽  
XiongBin Lin ◽  
...  
Keyword(s):  

Author(s):  
Javier Ramos-Maqueda ◽  
Adrián Riaño Ondiviela ◽  
Cristina Navarro-Valverde
Keyword(s):  

Author(s):  
Nathan El Bèze ◽  
Vincent Millien ◽  
Thierry Lefèvre ◽  
Bernard Chevalier ◽  
Philippe Garot ◽  
...  

2021 ◽  
Vol 10 (18) ◽  
pp. 4270
Author(s):  
Hack-Lyoung Kim ◽  
Sang-Ho Jo

Vasospastic angina (VSA) is characterized by a reversible spasm of the coronary arteries and is more prevalent in Asians. Vasodilators, such as calcium channel blockers, are effective in relieving coronary spasms and preventing clinical events. Therefore, the prognosis of VSA is generally known to be better than for significant organic stenosis caused by atherosclerosis. However, coronary vasospasm is sometimes associated with fatal complications such as sudden death, ventricular arrhythmia, and myocardial infarction. Thus, it is very important to identify and actively treat high-risk patients to prevent VSA complications. Here, we will review clinical factors associated with long-term prognosis in patients with VSA.


Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1632
Author(s):  
Hiroki Teragawa ◽  
Yuichi Orita ◽  
Chikage Oshita ◽  
Yuko Uchimura

Background: Despite significant interest in intracoronary thrombi in patients with vasospastic angina (VSA), the phenomenon remains unclarified. Therefore, we investigated a possible relationship using coronary angioscopy (CAS) in VSA patients. Methods: Sixty patients with VSA, for whom we could assess the spastic segment using CAS, were retrospectively studied. An intracoronary thrombus on CAS was a white thrombus and an erosion-like red thrombus. We verified the clinical characteristics and lesional characteristics as they determined the risk of intracoronary thrombus formation. Results: There were 18 (30%) patients with intracoronary thrombi. More of the patients with intracoronary thrombi were male, current smokers and had severe concomitant symptoms; however, no statistically significant difference was observed upon logistic regression analysis. There were 18 (26%) coronary arteries with intracoronary thrombi out of 70 coronary arteries recognised in the spastic segments. Furthermore, atherosclerotic changes and segmental spasms were significant factors responsible for such lesions. Conclusion: Intracoronary thrombi occurred in 30% of VSA patients and much attention should be paid to the intracoronary thrombogenicity of VSA patients.


Sign in / Sign up

Export Citation Format

Share Document